metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)
versus nivolumab alone
	nivolumab plus ipilimumab
	NRG GY003, 2020 J Clin Oncol 2020; 38:1814-1823 NCT02498600	RCT	metastatic/advanced OC (mOC) - 2nd line (L2)	nivolumab plus ipilimumab	nivolumab	patients with recurrent or persistent ovarian,primary peritoneal, or fallopian tube carcinoma of all histologic types except mucinous adenocarcinoma andcarcinosarcoma with history of primary platinum-basedchemotherapy with a maximum of three prior cytotoxicregimens and with at least one regimen for recurrentdisease containing a platinum or a taxane	49 / 51	some concern	inconclusive	suggested 47 % decrease in progression or deaths (PFS) suggested 2.3-fold increase in objective responses (ORR) (PE) statistically significant 1.3-fold increase in TRAE (grade 3-4)